Chelsea Therapeutics, Inc. (CHTP) Announces FDA Acceptance of NORTHERA (droxidopa) NDA Resubmission
7/17/2013 9:35:51 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
CHARLOTTE, N.C., July 17, 2013 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the New Drug Application (NDA) resubmission seeking approval to market NORTHERA™ (droxidopa), an orally active synthetic precursor of norepinephrine, for the treatment of symptomatic neurogenic orthostatic hypotension (NOH) in patients with primary autonomic failure (Parkinson's disease, multiple system atrophy and pure autonomic failure), dopamine beta hydroxylase deficiency and non-diabetic autonomic neuropathy. The FDA has deemed the resubmission a complete response to its March 28, 2012 Complete Response Letter and assigned a new Prescription Drug User Fee Act (PDUFA) goal date of January 3, 2014.
Help employers find you! Check out all the jobs and post your resume.
comments powered by